119434-75-2Relevant academic research and scientific papers
Enantioselective synthesis of (S)-3-(4-thiazolyl)-2-tert- butoxycarbonylaminopropionic acid: A chiral building block for renin inhibitor
Yuasa, Yoshifumi,Tsuruta, Haruki,Yuasa, Yoko
, p. 2385 - 2392 (2007/10/03)
(S)-3-(4-Thiazolyl)-2-tert-butoxycarbonylaminopropionic acid (6), an important structural constituent of the renin inhibitor, has been synthesized from (Z)-3-(4-thiazolyl)-2-benzoylaminoprop-2-enoic acid (4b) by enantioselective hydrogenation using the Ru
Antiparkinsonism drugs
-
, (2008/06/13)
A compound represented by the formula: wherein A is thiazolyl or the like, X is a bond or the like, m is an integer of 0 to 4, Y is optionally substituted alkyl or the like, Z is a substituent represented by the formula: wherein R3 is hydrogen atom or the like, R4 and R5 are each independently hydrogen atom or the like, W is —(CH2)n— (n is 0,1,2 or 3) or the like, a prodrug thereof, its pharmaceutically acceptable salt, or its solvate is useful as a composition for prevention or treatment of Parkinson's disease.
Peptide derivatives having thiazolyl-alanine residue
-
, (2008/06/13)
A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.
N-(Boc)-L-(2-bromoallyl)-glycine: A versatile intermediate for the synthesis of optically active unnatural amino acids
Leanna,Morton
, p. 4485 - 4488 (2007/10/02)
N(Boc)-L-(2-bromoallyl)-glycine (1) was synthesized from diethylacetamidomalonate and 2,3-dibromopropene in a one-pot procedure (75% overall yield). The enantiomers were efficiently separated via a tandem biocatalytic kinetic hydrolytic resolution. 1 was
ENCAPSULATED RENIN INHIBITOR COMPOSITION
-
, (2008/06/13)
A pharmaceutical composition comprising a solution of a tenin inhibitor of the formula: STR1 wherein R 1 is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R 2 is benzyl, p-methoxybenzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl;R 3 is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH 3 S--or CH 3 SCH 2--;R 4 is loweralkyl or cyclopropyl;R 5 is hydrogen or loweralkyl; andX is CH 2 or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof in a pharmaceutically acceptable solvent, said solution being encapsulated in a soft elastic gelatin capsule.
Psoriasis treatment
-
, (2008/06/13)
The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for treatment of psoriasis.
PEPTIDYL AMINODIOL RENIN INHIBITORS
-
, (2008/06/13)
A renin inhibiting compound having an aminodiol functional group is useful for treating hypertension, congestive heart failure and glaucoma and inhibits retroviral protease.
Synthesis of N-(tert-Butoxycarbonyl)-3-(4-thiazolyl)-L-alanine
Hsiao, Chi-Nung,Leanna, M. Robert,Bhagavatula, Lakshmi,Lara, Edvin De,Zydowsky, Thomas M.,et al.
, p. 3507 - 3517 (2007/10/02)
Efficient syntheses of N-(tert-butoxycarbonyl)-3-(4-thiazolyl)-L-alanine (11) are described.
